NTLA
Intellia Therapeutics, Inc.$12.07+0.15 (+1.26%)Prev Close$11.94·MCap$1.53B·P/E—·Vol644.2K·Yield—
▲
Buys (12M)
2
$2.41M
▼
Sells (12M)
16
$1.84M
◆
Net Activity
Net Buyer
$570.2K
●
Active Insiders
10
last 12 mo
Over the past 12 months, insider activity at Intellia Therapeutics, Inc. (NTLA) has been mixed between buying and selling, with 2 insider purchases totaling $2.41M and 16 insider sales totaling $1.84M. The most recent insider transaction was by BASTA JAMES (officer: EVP, General Counsel), who sold $16.7K worth of shares on Mar 3, 2026. Intellia Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.53B.
NTLA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | BASTA JAMES | officer: EVP, General Counsel | Sell | 1,211 | $13.78 | $16.7K | 156,794 |
| Mar 3, 2026 | Clark Eliana | officer: EVP, Chief Technical Officer | Sell | 607 | $13.78 | $8.4K | 93,864 |
| Jan 5, 2026 | BASTA JAMES | EVP, General Counsel | Sell | 10,397 | $9.21 | $95.8K | 0 |
| Jan 5, 2026 | Clark Eliana | EVP, Chief Technical Officer | Sell | 9,515 | $9.21 | $87.6K | 0 |
| Jan 5, 2026 | Cohen Fred E | Director | Buy | 150,000 | $9.35 | $1.40M | 0 |
| Jan 5, 2026 | Dube Michael P | VP, Chief Accounting Officer | Sell | 2,989 | $9.21 | $27.5K | 0 |
| Jan 5, 2026 | Dulac Edward J III | EVP, Chief Financial Officer | Sell | 6,379 | $9.21 | $58.8K | 0 |
| Jan 5, 2026 | Lebwohl David | EVP, Chief Medical Officer | Sell | 11,903 | $9.21 | $109.6K | 0 |
| Jan 5, 2026 | LEONARD JOHN M | President and CEO | Sell | 34,146 | $9.21 | $314.5K | 0 |
| Jan 5, 2026 | Schultes Birgit C | EVP, Chief Scientific Officer | Sell | 8,508 | $9.21 | $78.4K | 0 |
| Dec 11, 2025 | LEONARD JOHN M | President and CEO | Sell | 88,146 | $9.49 | $836.4K | 0 |
| Oct 1, 2025 | Dube Michael P | VP, Chief Accounting Officer | Sell | 1,871 | $17.38 | $32.5K | 0 |
| Oct 1, 2025 | Schultes Birgit C | EVP, Chief Scientific Officer | Sell | 31 | $17.38 | $538.78 | 0 |
| Aug 20, 2025 | CHASE WILLIAM J | Director | Buy | 100,000 | $10.03 | $1.00M | 0 |
| Jul 23, 2025 | Dulac Edward J III | EVP, Chief Financial Officer | Sell | 7,462 | $14.02 | $104.6K | 0 |
| Jul 2, 2025 | Dube Michael P | VP, Chief Accounting Officer | Sell | 2,503 | $9.95 | $24.9K | 0 |
| Jul 1, 2025 | Clark Eliana | EVP, Chief Technical Officer | Sell | 1,022 | $9.82 | $10.0K | 0 |
| Jun 30, 2025 | GOODMAN JESSE | Director | Sell | 3,094 | $9.39 | $29.1K | 0 |
| Apr 29, 2025 | Bhanji Muna | Director | Sell | 265 | $8.50 | $2.3K | 0 |
| Mar 1, 2025 | BASTA JAMES | EVP, General Counsel | Sell | 2,572 | $8.99 | $23.1K | 0 |
| Mar 1, 2025 | Clark Eliana | EVP, Chief Technical Officer | Sell | 679 | $8.99 | $6.1K | 0 |
| Jan 31, 2025 | Bhanji Muna | Sell | 265 | $9.97 | $2.6K | 19,468 | |
| Jan 7, 2025 | BASTA JAMES | EVP, General Counsel | Sell | 7,074 | $12.18 | $86.2K | 74,497 |
| Jan 7, 2025 | Dube Michael P | VP, Chief Accounting Officer | Sell | 1,372 | $12.18 | $16.7K | 45,640 |
| Jan 7, 2025 | Hicks Derek | EVP, Chief Business Officer | Sell | 6,502 | $12.18 | $79.2K | 59,878 |
| Jan 7, 2025 | Lebwohl David | EVP, Chief Medical Officer | Sell | 9,557 | $12.18 | $116.4K | 87,666 |
| Jan 7, 2025 | LEONARD JOHN M | President and CEO | Sell | 26,807 | $12.18 | $326.5K | 941,115 |
| Jan 7, 2025 | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Sell | 8,966 | $12.18 | $109.2K | 77,388 |
| Jan 6, 2025 | Clark Eliana | EVP, Chief Technical Officer | Sell | 7,978 | $12.17 | $97.1K | 71,470 |
| Oct 4, 2024 | Dube Michael P | VP, Chief Accounting Officer | Sell | 2,012 | $19.01 | $38.2K | 47,012 |
| Jul 3, 2024 | Clark Eliana | EVP, Chief Technical Officer | Sell | 405 | $22.93 | $9.3K | 71,470 |
| Jun 20, 2024 | Verwiel Frank | Sell | 1,505 | $25.00 | $37.6K | 17,948 | |
| Mar 5, 2024 | BASTA JAMES | EVP, General Counsel | Sell | 2,297 | $32.99 | $75.8K | 81,571 |
| Mar 5, 2024 | Clark Eliana | EVP, Chief Technical Officer | Sell | 605 | $32.99 | $20.0K | 71,470 |
| Jan 10, 2024 | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Sell | 2,275 | $28.87 | $65.7K | 44,594 |
| Jan 5, 2024 | BASTA JAMES | EVP, General Counsel | Sell | 3,805 | $29.46 | $112.1K | 51,474 |
| Jan 5, 2024 | Clark Eliana | EVP, Chief Technical Officer | Sell | 4,608 | $29.50 | $136.0K | 45,146 |
| Jan 5, 2024 | Goddard Glenn | EVP, Chief Financial Officer | Sell | 5,365 | $29.46 | $158.1K | 40,585 |
| Jan 5, 2024 | Hicks Derek | EVP, Chief Business Officer | Sell | 3,877 | $29.46 | $114.2K | 36,987 |
| Jan 5, 2024 | Lebwohl David | EVP, Chief Medical Officer | Sell | 5,843 | $29.46 | $172.1K | 54,372 |
| Jan 5, 2024 | LEONARD JOHN M | President and CEO | Sell | 19,223 | $29.46 | $566.3K | 846,486 |
| Jan 5, 2024 | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Sell | 5,532 | $29.46 | $163.0K | 46,202 |
| Nov 2, 2023 | Bhanji Muna | Director | Sell | 265 | $23.90 | $6.3K | 11,996 |
| Aug 2, 2023 | Bhanji Muna | Director | Sell | 265 | $42.33 | $11.2K | 12,261 |
| Jul 10, 2023 | Bhanji Muna | Director | Sell | 1,867 | $39.30 | $73.4K | 12,526 |
| Jul 6, 2023 | Clark Eliana | EVP, Chief Technical Officer | Sell | 360 | $40.51 | $14.6K | 45,146 |
| Jun 22, 2023 | Clark Eliana | EVP, Chief Technical Officer | Sell | 5,000 | $45.00 | $225.0K | 45,146 |
| Mar 3, 2023 | BASTA JAMES | EVP, General Counsel | Sell | 1,088 | $43.88 | $47.7K | 55,279 |
| Jan 6, 2023 | BASTA JAMES | EVP, General Counsel | Sell | 1,138 | $37.21 | $42.3K | 19,559 |
| Jan 6, 2023 | Clark Eliana | EVP, Chief Technical Officer | Sell | 2,028 | $37.65 | $76.4K | 16,165 |
Showing 1–50 of 82
1 / 2
NTLA Insider Buying Activity
The following table shows recent insider purchases of Intellia Therapeutics, Inc. (NTLA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Cohen Fred E | Director | Buy | 150,000 | $9.35 | $1.40M | 0 |
| Aug 20, 2025 | CHASE WILLIAM J | Director | Buy | 100,000 | $10.03 | $1.00M | 0 |
NTLA Insider Selling Activity
The following table shows recent insider sales of Intellia Therapeutics, Inc. (NTLA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | BASTA JAMES | officer: EVP, General Counsel | Sell | 1,211 | $13.78 | $16.7K | 156,794 |
| Mar 3, 2026 | Clark Eliana | officer: EVP, Chief Technical Officer | Sell | 607 | $13.78 | $8.4K | 93,864 |
| Jan 5, 2026 | BASTA JAMES | EVP, General Counsel | Sell | 10,397 | $9.21 | $95.8K | 0 |
| Jan 5, 2026 | Clark Eliana | EVP, Chief Technical Officer | Sell | 9,515 | $9.21 | $87.6K | 0 |
| Jan 5, 2026 | Dube Michael P | VP, Chief Accounting Officer | Sell | 2,989 | $9.21 | $27.5K | 0 |
| Jan 5, 2026 | Dulac Edward J III | EVP, Chief Financial Officer | Sell | 6,379 | $9.21 | $58.8K | 0 |
| Jan 5, 2026 | Lebwohl David | EVP, Chief Medical Officer | Sell | 11,903 | $9.21 | $109.6K | 0 |
| Jan 5, 2026 | LEONARD JOHN M | President and CEO | Sell | 34,146 | $9.21 | $314.5K | 0 |
| Jan 5, 2026 | Schultes Birgit C | EVP, Chief Scientific Officer | Sell | 8,508 | $9.21 | $78.4K | 0 |
| Dec 11, 2025 | LEONARD JOHN M | President and CEO | Sell | 88,146 | $9.49 | $836.4K | 0 |
| Oct 1, 2025 | Dube Michael P | VP, Chief Accounting Officer | Sell | 1,871 | $17.38 | $32.5K | 0 |
| Oct 1, 2025 | Schultes Birgit C | EVP, Chief Scientific Officer | Sell | 31 | $17.38 | $538.78 | 0 |
| Jul 23, 2025 | Dulac Edward J III | EVP, Chief Financial Officer | Sell | 7,462 | $14.02 | $104.6K | 0 |
| Jul 2, 2025 | Dube Michael P | VP, Chief Accounting Officer | Sell | 2,503 | $9.95 | $24.9K | 0 |
| Jul 1, 2025 | Clark Eliana | EVP, Chief Technical Officer | Sell | 1,022 | $9.82 | $10.0K | 0 |
| Jun 30, 2025 | GOODMAN JESSE | Director | Sell | 3,094 | $9.39 | $29.1K | 0 |
| Apr 29, 2025 | Bhanji Muna | Director | Sell | 265 | $8.50 | $2.3K | 0 |
| Mar 1, 2025 | BASTA JAMES | EVP, General Counsel | Sell | 2,572 | $8.99 | $23.1K | 0 |
| Mar 1, 2025 | Clark Eliana | EVP, Chief Technical Officer | Sell | 679 | $8.99 | $6.1K | 0 |
| Jan 31, 2025 | Bhanji Muna | Sell | 265 | $9.97 | $2.6K | 19,468 | |
| Jan 7, 2025 | BASTA JAMES | EVP, General Counsel | Sell | 7,074 | $12.18 | $86.2K | 74,497 |
| Jan 7, 2025 | Dube Michael P | VP, Chief Accounting Officer | Sell | 1,372 | $12.18 | $16.7K | 45,640 |
| Jan 7, 2025 | Hicks Derek | EVP, Chief Business Officer | Sell | 6,502 | $12.18 | $79.2K | 59,878 |
| Jan 7, 2025 | Lebwohl David | EVP, Chief Medical Officer | Sell | 9,557 | $12.18 | $116.4K | 87,666 |
| Jan 7, 2025 | LEONARD JOHN M | President and CEO | Sell | 26,807 | $12.18 | $326.5K | 941,115 |
| Jan 7, 2025 | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Sell | 8,966 | $12.18 | $109.2K | 77,388 |
| Jan 6, 2025 | Clark Eliana | EVP, Chief Technical Officer | Sell | 7,978 | $12.17 | $97.1K | 71,470 |
| Oct 4, 2024 | Dube Michael P | VP, Chief Accounting Officer | Sell | 2,012 | $19.01 | $38.2K | 47,012 |
| Jul 3, 2024 | Clark Eliana | EVP, Chief Technical Officer | Sell | 405 | $22.93 | $9.3K | 71,470 |
| Jun 20, 2024 | Verwiel Frank | Sell | 1,505 | $25.00 | $37.6K | 17,948 | |
| Mar 5, 2024 | BASTA JAMES | EVP, General Counsel | Sell | 2,297 | $32.99 | $75.8K | 81,571 |
| Mar 5, 2024 | Clark Eliana | EVP, Chief Technical Officer | Sell | 605 | $32.99 | $20.0K | 71,470 |
| Jan 10, 2024 | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Sell | 2,275 | $28.87 | $65.7K | 44,594 |
| Jan 5, 2024 | BASTA JAMES | EVP, General Counsel | Sell | 3,805 | $29.46 | $112.1K | 51,474 |
| Jan 5, 2024 | Clark Eliana | EVP, Chief Technical Officer | Sell | 4,608 | $29.50 | $136.0K | 45,146 |
| Jan 5, 2024 | Goddard Glenn | EVP, Chief Financial Officer | Sell | 5,365 | $29.46 | $158.1K | 40,585 |
| Jan 5, 2024 | Hicks Derek | EVP, Chief Business Officer | Sell | 3,877 | $29.46 | $114.2K | 36,987 |
| Jan 5, 2024 | Lebwohl David | EVP, Chief Medical Officer | Sell | 5,843 | $29.46 | $172.1K | 54,372 |
| Jan 5, 2024 | LEONARD JOHN M | President and CEO | Sell | 19,223 | $29.46 | $566.3K | 846,486 |
| Jan 5, 2024 | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Sell | 5,532 | $29.46 | $163.0K | 46,202 |
| Nov 2, 2023 | Bhanji Muna | Director | Sell | 265 | $23.90 | $6.3K | 11,996 |
| Aug 2, 2023 | Bhanji Muna | Director | Sell | 265 | $42.33 | $11.2K | 12,261 |
| Jul 10, 2023 | Bhanji Muna | Director | Sell | 1,867 | $39.30 | $73.4K | 12,526 |
| Jul 6, 2023 | Clark Eliana | EVP, Chief Technical Officer | Sell | 360 | $40.51 | $14.6K | 45,146 |
| Jun 22, 2023 | Clark Eliana | EVP, Chief Technical Officer | Sell | 5,000 | $45.00 | $225.0K | 45,146 |
| Mar 3, 2023 | BASTA JAMES | EVP, General Counsel | Sell | 1,088 | $43.88 | $47.7K | 55,279 |
| Jan 6, 2023 | BASTA JAMES | EVP, General Counsel | Sell | 1,138 | $37.21 | $42.3K | 19,559 |
| Jan 6, 2023 | Clark Eliana | EVP, Chief Technical Officer | Sell | 2,028 | $37.65 | $76.4K | 16,165 |
NTLA Insiders
Similar Stocks to NTLA
VRTX
Vertex Pharmaceuticals Incorporated
$433.43-0.23%
$114.32B
REGN
Regeneron Pharmaceuticals, Inc.
$650.02+3.06%
$73.44B
ALNY
Alnylam Pharmaceuticals, Inc.
$295.66+0.33%
$39.18B
RVMD
Revolution Medicines, Inc.
$151.00+2.39%
$31.78B
INSM
Insmed Incorporated
$107.92+0.64%
$25.06B
UTHR
United Therapeutics Corporation
$572.17+0.78%
$24.13B
ROIV
Roivant Sciences Ltd.
$31.63+11.84%
$20.96B
MRNA
Moderna, Inc.
$46.95+2.78%
$19.46B